Efficacy and Safety of Tocilizumab in Adult's Still Disease
Status:
Unknown status
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Patients with adult's Still disease suffer from acute inflammatory symptoms such as fever,
arthritis, rash, and acute phase response often requiring high dose corticosteroids. In view
of several case reports which have shown dramatic improvement in patients treated with
Tocilizumab and a phase 2 study of this drug in children with Still's disease, the objective
of the current study is to assess the efficacy and safety of Tocilizumab in patients with
adult's Still disease.
Phase:
Phase 2
Details
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Collaborators:
Assaf-Harofeh Medical Center Bnai Zion Medical Center Rambam Health Care Campus